Order a Test
New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors. The section below describes the breadth of testing provided by the Molecular Intelligence profile, ensuring that these discoveries are at the forefront of patient care.
MI Profile
Comprehensive Tumor Profiling
The Caris Molecular Intelligence® comprehensive tumor profiling approach to assess DNA, RNA and proteins reveals a molecular blueprint to guide more precise and individualized treatment decisions from about 60+ FDA-approved therapies.
DNA
Whole Exome Sequencing
(Mutations, Indels & Copy Number Alterations)
RNA
Whole Transcriptome Sequencing
(Fusions & Variant Transcripts)
Protein
Immunohistochemistry
Biomarker Analysis by Tumor Type
The information below details the biomarkers analyzed by technology for the tumor type submitted. Before ordering testing services, please refer to this profile menu to view the most-up-to date listing of biomarkers that will be performed. Tests may vary if samples with insufficient tissue are submitted.
All Biomarker Analysis includes:
Next-Generation Sequencing (NGS)
DNA
Genomic Signatures
Mutation
MSI
CNA Analysis
TMB
Whole Transcriptome Sequencing (WTS)
Fusion Analysis
Additional Testing:
Select tumor type to see specific tests to be performed.
TUMOR TYPE:
Immunohistochemistry (IHC)
Other
(NO TUMOR TYPE SELECTED).
Caris applies the appropriate tumor-specific customizations standard with every MI Profile test order.